First-to-File, First to Win: Lupin’s Tolvaptan Triumph Targets $1.47 Billion U.S. Market

Unknown Apr 02, 2026 700 Views

Global pharma major Lupin Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its generic Tolvaptan Tablets (15 mg, 30 mg, 45 mg, 60 mg, and 90 mg), marking a strategic milestone in its U.S. expansion. As the exclusive first-to-file generic manufacturer, Lupin...